Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Indraprastha Medical's annualized ROCE % for the quarter that ended in Mar. 2026 was 27.50%.
Indraprastha Medical (BOM:532150) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indraprastha Medical (BOM:532150) has a ROCE % of 27.50% as of Mar. 2026.
Is Indraprastha Medical's ROCE % too high?
Indraprastha Medical's current ROCE % is 27.50%. The Healthcare Providers & Services industry median ROCE % is 6.63. Indraprastha Medical's value of 27.50% is 314.8% above this industry median. Overall, Indraprastha Medical has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Indraprastha Medical's ROCE % compare to HCA and THC?
Indraprastha Medical's ROCE % of 27.50% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.63. Indraprastha Medical's value of 27.50% is 314.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.63, based on 643 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indraprastha Medical's current ROCE % of 27.50% is 314.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indraprastha Medical's current ROCE % is 27.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indraprastha Medical stock overvalued right now?
Based on GuruFocus' analysis, Indraprastha Medical (BOM:532150) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹428.14, compared to a current price of ₹376.95 — trading 12% below its estimated fair value. The current ROCE % is 27.50% and 314.8% above the Healthcare Providers & Services industry median of 6.63. Indraprastha Medical's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Indraprastha Medical (BOM:532150), the current ROCE % is 27.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indraprastha Medical (BOM:532150) Overvalued in 2026?
Based on GuruFocus' analysis, Indraprastha Medical stock appears to be undervalued.
The current stock price of ₹376.95 is trading 12% below its estimated GF Value™ of ₹428.14.
GuruFocus considers Indraprastha Medical to be Modestly Undervalued.
Key valuation signals for BOM:532150:
ROCE %: 27.50%
GF Value™: ₹428.14 vs. price of ₹376.95 (12% below fair value)
Industry Position: 314.8% above the Healthcare Providers & Services median
No single metric tells the full story. See the BOM:532150 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indraprastha Medical Corp Ltd is an Indian company that operates in the healthcare business. It offers services in the field of anaesthesiology, pediatrics, bone marrow transplant, dental surgery, neonatology, dermatology, obesity, and metabolic surgery, orthopaedics, robotic surgery, spine surgery and in many other areas. The company also provides diagnosis, treatment, and management of various hormonal disorders; and inpatient and ambulatory care services. Geographically all the business activities of the group are carried out through the regions of India. It derives revenue from the provision of services.
81GF Score
Get the complete analysis for BOM:532150
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532150 has been successfully added to your 
